| 1. Marciniak G, Delgado A, Leclerc G, Velly J, Decker N, Schwartz J.. (1989) New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties., 32 (6): [PMID:2542561] [10.1021/jm00126a042] |
| 2. Arrowsmith JE, Campbell SF, Cross PE, Stubbs JK, Burges RA, Gardiner DG, Blackburn KJ.. (1986) Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents., 29 (9): [PMID:2943898] [10.1021/jm00159a022] |
| 3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 4. Suomalainen P, Johans C, Söderlund T, Kinnunen PK.. (2004) Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability., 47 (7): [PMID:15027870] [10.1021/jm0309001] |
| 5. Cho H, Ueda M, Shima K, Mizuno A, Hayashimatsu M, Ohnaka Y, Takeuchi Y, Hamaguchi M, Aisaka K, Hidaka T.. (1989) Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity., 32 (10): [PMID:2552119] [10.1021/jm00130a029] |
| 6. Tamazawa K, Arima H, Kojima T, Isomura Y, Okada M, Fujita S, Furuya T, Takenaka T, Inagaki O, Terai M.. (1986) Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate., 29 (12): [PMID:3023614] [10.1021/jm00162a013] |
| 7. Yoshida F, Topliss JG.. (2000) QSAR model for drug human oral bioavailability., 43 (13): [PMID:10891117] [10.1021/jm0000564] |
| 8. Bruno-Blanch L, Gálvez J, García-Domenech R.. (2003) Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity., 13 (16): [PMID:12873507] [10.1016/s0960-894x(03)00535-3] |
| 9. Tasaka S, Ohmori H, Gomi N, Iino M, Machida T, Kiue A, Naito S, Kuwano M.. (2001) Synthesis and structure--activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance., 11 (2): [PMID:11206476] [10.1016/s0960-894x(00)00651-x] |
| 10. van Rhee AM, Jiang JL, Melman N, Olah ME, Stiles GL, Jacobson KA.. (1996) Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors., 39 (15): [PMID:8709132] [10.1021/jm9600205] |
| 11. McGovern SL, Helfand BT, Feng B, Shoichet BK.. (2003) A specific mechanism of nonspecific inhibition., 46 (20): [PMID:13678405] [10.1021/jm030266r] |
| 12. Belciug MP, Ananthanarayanan VS.. (1994) Interaction of calcium channel antagonists with calcium: structural studies on nicardipine and its Ca2+ complex., 37 (25): [PMID:7996551] [10.1021/jm00051a017] |
| 13. Seidler J, McGovern SL, Doman TN, Shoichet BK.. (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs., 46 (21): [PMID:14521410] [10.1021/jm030191r] |
| 14. Schneider G, Coassolo P, Lavé T.. (1999) Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques., 42 (25): [PMID:10602692] [10.1021/jm991030j] |
| 15. Janis RA, Triggle DJ.. (1983) New developments in Ca2+ channel antagonists., 26 (6): [PMID:6304312] [10.1021/jm00360a001] |
| 16. Afzelius L, Zamora I, Masimirembwa CM, Karlén A, Andersson TB, Mecucci S, Baroni M, Cruciani G.. (2004) Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors., 47 (4): [PMID:14761192] [10.1021/jm030972s] |
| 17. Yamamoto K, Fujita M, Tabashi K, Kawashima Y, Kato E, Oya M, Iso T, Iwao J.. (1988) Novel calcium antagonists. Synthesis and structure-activity relationship studies of benzothiazoline derivatives., 31 (5): [PMID:3361580] [10.1021/jm00400a006] |
| 18. Ermondi G, Lorenti M, Caron G.. (2004) Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction., 47 (16): [PMID:15267234] [10.1021/jm040760a] |
| 19. Müller H, Klinkhammer W, Globisch C, Kassack MU, Pajeva IK, Wiese M.. (2007) New functional assay of P-glycoprotein activity using Hoechst 33342., 15 (23): [PMID:17890094] [10.1016/j.bmc.2007.07.024] |
| 20. Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, Yuan J.. (2007) Small molecule regulators of autophagy identified by an image-based high-throughput screen., 104 (48): [PMID:18024584] [10.1073/pnas.0709695104] |
| 21. Pick A, Müller H, Wiese M.. (2008) Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)., 16 (17): [PMID:18678495] [10.1016/j.bmc.2008.07.034] |
| 22. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.. (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)., 51 (11): [PMID:18457386] [10.1021/jm7015683] |
| 23. Sanchez AM, Thomas D, Gillespie EJ, Damoiseaux R, Rogers J, Saxe JP, Huang J, Manchester M, Bradley KA.. (2007) Amiodarone and bepridil inhibit anthrax toxin entry into host cells., 51 (7): [PMID:17485504] [10.1128/aac.01184-06] |
| 24. Roh EJ, Keller JM, Olah Z, Iadarola MJ, Jacobson KA.. (2008) Structure-activity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1)., 16 (20): [PMID:18809334] [10.1016/j.bmc.2008.08.048] |
| 25. Coan KE, Maltby DA, Burlingame AL, Shoichet BK.. (2009) Promiscuous aggregate-based inhibitors promote enzyme unfolding., 52 (7): [PMID:19281222] [10.1021/jm801605r] |
| 26. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.. (2009) Physicochemical determinants of human renal clearance., 52 (15): [PMID:19445515] [10.1021/jm900403j] |
| 27. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.. (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination., 53 (3): [PMID:20070106] [10.1021/jm901371v] |
| 28. Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.. (2009) Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data., 44 (11): [PMID:19586686] [10.1016/j.ejmech.2009.06.004] |
| 29. Baraldi PG, Preti D, Materazzi S, Geppetti P.. (2010) Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents., 53 (14): [PMID:20356305] [10.1021/jm100062h] |
| 30. Feng BY, Toyama BH, Wille H, Colby DW, Collins SR, May BC, Prusiner SB, Weissman J, Shoichet BK.. (2008) Small-molecule aggregates inhibit amyloid polymerization., 4 (3): [PMID:18223646] [10.1038/nchembio.65] |
| 31. Chen CY, Yang YH, Kuo SY.. (2010) Effect of [6]-shogaol on cytosolic Ca2+ levels and proliferation in human oral cancer cells (OC2)., 73 (8): [PMID:20669930] [10.1021/np100213a] |
| 32. Reimão JQ, Scotti MT, Tempone AG.. (2010) Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study., 18 (22): [PMID:20934347] [10.1016/j.bmc.2010.09.015] |
| 33. PubChem BioAssay data set, |
| 34. PubChem BioAssay data set, |
| 35. PubChem BioAssay data set, |
| 36. Jolivette LJ, Ward KW.. (2005) Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure., 94 (7): [PMID:15920768] [10.1002/jps.20373] |
| 37. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 38. Ward KW, Nagilla R, Jolivette LJ.. (2005) Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human., 35 (2): [PMID:16019946] [10.1080/00498250400028197] |
| 39. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.. (2004) Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling., 1 (4): [PMID:16472241] [10.2174/1570163043334794] |
| 40. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 41. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 42. PubChem BioAssay data set, |
| 43. PubChem BioAssay data set, |
| 44. PubChem BioAssay data set, |
| 45. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.. (2001) Rational use of in vitro P-glycoprotein assays in drug discovery., 299 (2): [PMID:11602674] |
| 46. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 47. Sun H.. (2012) Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism., 22 (2): [PMID:22197392] [10.1016/j.bmcl.2011.12.005] |
| 48. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A.. (2000) Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation., 295 (1): [PMID:11082465] |
| 49. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 50. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.. (2001) Rational use of in vitro P-glycoprotein assays in drug discovery., 299 (2): [PMID:11602674] |
| 51. Wang EJ, Casciano CN, Clement RP, Johnson WW.. (2001) Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors., 289 (1): [PMID:11716514] [10.1006/bbrc.2001.6000] |
| 52. Katoh M, Nakajima M, Yamazaki H, Yokoi T.. (2000) Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4., 17 (1): [PMID:11145223] [10.1023/a:1007568811691] |
| 53. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K.. (2002) Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression., 16 (1): [PMID:12128170] [10.1016/s0928-0987(02)00082-9] |
| 54. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE.. (2000) Influence of passive permeability on apparent P-glycoprotein kinetics., 17 (1): [PMID:11303953] [10.1023/a:1007692622216] |
| 55. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.. (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions., 55 (10): [PMID:22541068] [10.1021/jm300212s] |
| 56. Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ.. (2012) Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2., 22 (24): [PMID:23122865] [10.1016/j.bmcl.2012.10.010] |
| 57. Gupta V, Misra U. (2008) Synthesis and cardiovascular activity of difluro-substituted hexahydroquinoline, 17 (2): [10.1007/s00044-007-9078-8] |
| 58. PubChem BioAssay data set, |
| 59. PubChem BioAssay data set, |
| 60. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 61. PubChem BioAssay data set, |
| 62. Mateus A, Matsson P, Artursson P.. (2014) A high-throughput cell-based method to predict the unbound drug fraction in the brain., 57 (7): [PMID:24601604] [10.1021/jm401963n] |
| 63. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 64. Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S.. (2012) Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment., 32 [PMID:22761000] [10.1002/jat.2784] |
| 65. Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.. (2012) Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity., 40 (5): [PMID:22328583] [10.1124/dmd.111.043505] |
| 66. Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.. (2013) Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors., 41 (1): [PMID:23033255] [10.1124/dmd.112.048264] |
| 67. Curran RE, Claxton CR, Hutchison L, Harradine PJ, Martin IJ, Littlewood P.. (2011) Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding., 39 (3): [PMID:21098647] [10.1124/dmd.110.036988] |
| 68. Lin X, Skolnik S, Chen X, Wang J.. (2011) Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model., 39 (2): [PMID:21051535] [10.1124/dmd.110.034629] |
| 69. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE.. (2011) Species independence in brain tissue binding using brain homogenates., 39 (7): [PMID:21474681] [10.1124/dmd.111.038778] |
| 70. (2014) Agents and methods for treating ischemic and other diseases, |
| 71. Zmuda F, Malviya G, Blair A, Boyd M, Chalmers AJ, Sutherland A, Pimlott SL.. (2015) Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo., 58 (21): [PMID:26469301] [10.1021/acs.jmedchem.5b01324] |
| 72. WHO Anatomical Therapeutic Chemical Classification, |
| 73. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development., 118 (2): [PMID:20829430] [10.1093/toxsci/kfq269] |
| 74. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.. (2014) Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump., 60 (3): [PMID:24799086] [10.1002/hep.27206] |
| 75. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification., 40 (12): [PMID:22961681] [10.1124/dmd.112.047068] |
| 76. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 77. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 78. Astolfi A, Felicetti T, Iraci N, Manfroni G, Massari S, Pietrella D, Tabarrini O, Kaatz GW, Barreca ML, Sabatini S, Cecchetti V.. (2017) Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors., 60 (4): [PMID:28117588] [10.1021/acs.jmedchem.6b01439] |
| 79. Devine SM, Yong C, Amenuvegbe D, Aurelio L, Muthiah D, Pouton C, Callaghan R, Capuano B, Scammells PJ.. (2018) Synthesis and Pharmacological Evaluation of Noscapine-Inspired 5-Substituted Tetrahydroisoquinolines as Cytotoxic Agents., 61 (18): [PMID:30156410] [10.1021/acs.jmedchem.8b00986] |
| 80. Iwata M, Hirose L, Kohara H, Liao J, Sawada R, Akiyoshi S, Tani K, Yamanishi Y.. (2018) Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation., 61 (21): [PMID:30371064] [10.1021/acs.jmedchem.8b01044] |
| 81. Unpublished dataset, |
| 82. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 83. Zhu Y, Sun N, Yu M, Guo H, Xie Q, Wang Y.. (2019) Discovery of aryl-substituted indole and indoline derivatives as RORγt agonists., 182 [PMID:31425906] [10.1016/j.ejmech.2019.111589] |
| 84. Boulton S, Selvaratnam R, Ahmed R, Van K, Cheng X, Melacini G.. (2019) Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators., 62 (10): [PMID:31074269] [10.1021/acs.jmedchem.9b00258] |
| 85. Kandil S, Pannecouque C, Chapman FM, Westwell AD, McGuigan C.. (2019) Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity., 29 (24): [PMID:31679972] [10.1016/j.bmcl.2019.126721] |
| 86. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 87. Norman BH. (2020) Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies., 63 (20.0): [PMID:32511920] [10.1021/acs.jmedchem.0c00524] |
| 88. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 89. Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR, Valdameri G.. (2022) Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators., 237 [PMID:35483322] [10.1016/j.ejmech.2022.114346] |
| 90. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
